Presentation 62,63
Presentation 62
Development Of A Novel Nano-lmmunological-Complex As An Anti-infectious Disease Treatment
Dr. Yosef Pinchasov
Yamit Biotechnologyies Ltd
**********************
Immunotherapy is a novel medical approach that is gaining growing interest in various medicine fields and could offer an alternative for conventional antibiotic medications. Immunotherapy is defined as a process designated to stimulate the body's own defensive immunological system into confronting harmful foreign bodies, (e.g. bacteria and viruses). Bovine Mastitis - an inflammatory disease of the udders- is still today the most expensive disease occurring in dairy cows, despite the numerous endeavors invested in its prevention; hitherto, treatments resulted only in partial success, and the most effective treatment to date (50% success rate) is still based on antibiotics use.
Recently, as the western world's preference towards non-antibiotic treatments in the food chain has grown, the time is ripe for reducing the use of antibiotics in treating mastitis in dairy farms, Y-Complex is an innovative immunological platform developed as treatment for diseases caused by recognized pathogens. The Complex comprises three key elements: a) A micro- or nano-carrier coated with b) Antibodies ("Ab's") designed to target specific pathogens and an c) inducer of phagocytes and neutrophils. When the Complex is administered into an infected organ, the following events occur: the invaded bacteria pathogens are actively bound to the Y-Complexｮ following by the attraction of phagocytes via a specific inducer displayed on the Y-Complex surface.
This process leads to the macrophage engulfing the whole bacteria-carrier complex, and disabling the pathogen attack. We show in an in vitro experiment that a Y-Complexｮ using a 1-um-polystyrene carrier did recognize and bind a specific bacteria pathogen, and additionally that the presence of cow phagocytes significantly increased the disappearance.
********************
Presentation 63
BiondFlu - The Unuversal Flu Vaccine
Ron Babecoff, CEO Shira Frimer, Assistant
BiondVax Pharmaceuticals Ltd
********************
Marketing Plan The company has secured initial financing to cover the execution of its development program from preclinical studies through phase I clinical trials (scheduled for Q1 2007) and phase I la clinical trials (by year-end 2007). The later stage clinical trials will be done in collaboration with one of the leading global pharmaceutical companies. In parallel, BiondVax intends to further develop its platform vaccine technology to create new vaccines against other pathogens. The company is conducting animal trials in collaboration with the Israeli Veterinarian Institute to evaluate the efficacy of its unique vaccine formulation against various AⅤian Flu strains.
The Company BiondVax Pharmaceuticals Ltd. is developing an innovative universal intranasal flu (influenza) vaccine, providing a multi-season/multi-strain and long-term protection against variety flu viruses. The company holds a worldwide exclusive license from the Weizmann Institute. The team includes ten scientists and lab technicians, all experts in their fields and is presently operating at a new state of the art facility located in the Science Park, Nes Ziona, Israel. The Technology BiondVax's innovative synthetic peptide-based vaccine represents a quantum leap in the flu vaccine arena.
Conceptualized by Professor Ruth Arnon (Copaxone・co-developer, a billion dollar drug for the treatment of multiple sclerosis) and her team at the Weizmann Institute, and based on over 20 years of research, it demonstrates significantly higher efficacy levels, longer vaccination periods and a broader range of virus strain coverage than any other vaccine available in the market. The vaccine is based on a mixture of peptides from different viral proteins that are immunogenic,
conserved and common to the
